




PHARMACEUTICAL 2021

Pacira BioSciences Inc.
Rank 170 of 402





RealRate

PHARMACEUTICAL 2021

Pacira BioSciences Inc.
Rank 170 of 402



The relative strengths and weaknesses of Pacira BioSciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pacira BioSciences Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 72% points. The greatest weakness of Pacira BioSciences Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is 126%, being 78% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	651,623
Cost of Goods Sold	117,328
Intangible Assets	196,068
Liabilities, Current	253,328
Liabilities, Non-Current	74,857
Other Assets	290,134
Other Compr. Net Income	-4.0
Other Expenses	-112,402
Other Liabilities	326,640
Other Net Income	-26,261
Other Revenues	429,647
Property and Equipment	136,688
Research and Development	59,421
Selling, General and Administrative Expense	193,516

Output Variable	Value in 1000 USD
Assets	1,274,513
Liabilities	654,825
Expenses	257,863
Revenues	429,647
Stockholders Equity	619,688
Net Income	145,523
Comprehensive Net Income	145,521
Economic Capital Ratio	126%